Brief: Coya Therapeutics Announces Agreement With Dr. Reddy's Laboratories To License Its Proposed Biosimilar Abatacept For Development And Commercialization Of Coya 302 For Treatment Of Neurodegenerative Diseases
20/03/2023 11:08
March 20 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA THERAPEUTICS, INC. ANNOUNCES AN AGREEMENT WITH DR.
REDDY’S
LABORATORIES, LTD. TO LICENSE ITS PROPOSED BIOSIMILAR ABATACEPT
FOR THE DEVELOPMENT AND COMMERCIALIZATION OF COYA 302 FOR THE
TREATMENT OF NEURODEGENERATIVE DISEASES
* COYA THERAPEUTICS INC: AS PART OF DEVELOPMENT OF
COMBINATION
PRODUCT COYA 302, COYA WILL SOURCE CTLA4-IG FROM DR. REDDY'S
* COYA THERAPEUTICS : CO RETAINS EXCLUSIVE RIGHTS TO DEVELOP
AND
COMMERCIALIZE COYA 302 ACROSS MULTIPLE NEURODEGENERATIVE
DISEASES IN MANY TERRITORIES
* COYA: DR. REDDY'S OBTAINS EXCLUSIVE RIGHTS TO
COMMERCIALIZE COYA
302 ACROSS MULTIPLE NEURODEGENERATIVE DISEASES IN AREAS OUTSIDE
OF CO'S TERRITORY
* COYA THERAPEUTICS INC: ANTICIPATES IT WILL FILE AN IND FOR
COYA
302 IN 2H OF 2023 WITH GOAL OF INITIATING A PHASE 1B/2 TRIAL IN
ALS SOON THEREAFTER
Source text for Eikon: ID:nBw8lc2JGa
Further company coverage: COYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)